User menu

Preventive Strategies against Bleeding due to Nonvitamin KAntagonist Oral Anticoagulants

Bibliographic reference Lessire, Sarah ; Dincq, Anne-Sophie ; Douxfils, Jonathan ; Devalet, Bérangère ; Nicolas, Jean-Baptiste ; et. al. Preventive Strategies against Bleeding due to Nonvitamin KAntagonist Oral Anticoagulants. In: BioMed Research International, Vol. 2014, no. 616405, p. 1-14 (2014)
Permanent URL http://hdl.handle.net/2078.1/146109
  1. Journal of Thrombosis and Haemostasis, 111 (2014)
  2. Eriksson Bengt I, Dahl Ola E, Rosencher Nadia, Kurth Andreas A, van Dijk C Niek, Frostick Simon P, Prins Martin H, Hettiarachchi Rohan, Hantel Stefan, Schnee Janet, Büller Harry R, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, 10.1016/s0140-6736(07)61445-7
  3. Lassen Michael R., Ageno Walter, Borris Lars C., Lieberman Jay R., Rosencher Nadia, Bandel Tiemo J., Misselwitz Frank, Turpie Alexander G.G., Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty, 10.1056/nejmoa076016
  4. Granger Christopher B., Alexander John H., McMurray John J.V., Lopes Renato D., Hylek Elaine M., Hanna Michael, Al-Khalidi Hussein R., Ansell Jack, Atar Dan, Avezum Alvaro, Bahit M. Cecilia, Diaz Rafael, Easton J. Donald, Ezekowitz Justin A., Flaker Greg, Garcia David, Geraldes Margarida, Gersh Bernard J., Golitsyn Sergey, Goto Shinya, Hermosillo Antonio G., Hohnloser Stefan H., Horowitz John, Mohan Puneet, Jansky Petr, Lewis Basil S., Lopez-Sendon Jose Luis, Pais Prem, Parkhomenko Alexander, Verheugt Freek W.A., Zhu Jun, Wallentin Lars, Apixaban versus Warfarin in Patients with Atrial Fibrillation, 10.1056/nejmoa1107039
  5. The New England Journal of Medicine, 361, 2674 (2009)
  6. Patel Manesh R., Mahaffey Kenneth W., Garg Jyotsna, Pan Guohua, Singer Daniel E., Hacke Werner, Breithardt Günter, Halperin Jonathan L., Hankey Graeme J., Piccini Jonathan P., Becker Richard C., Nessel Christopher C., Paolini John F., Berkowitz Scott D., Fox Keith A.A., Califf Robert M., , Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, 10.1056/nejmoa1009638
  7. The New England Journal of Medicine, 363, 2499 (2010)
  8. , Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism, 10.1056/nejmoa1113572
  9. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM, Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial, 10.1016/s0140-6736(09)60738-8
  10. The New England Journal of Medicine, 366, 9 (2012)
  11. Hylek Elaine M., Held Claes, Alexander John H., Lopes Renato D., De Caterina Raffaele, Wojdyla Daniel M., Huber Kurt, Jansky Petr, Steg Philippe Gabriel, Hanna Michael, Thomas Laine, Wallentin Lars, Granger Christopher B., Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin, 10.1016/j.jacc.2014.02.549
  12. Thrombosis and Haemostasis, 108, 903 (2012)
  13. Southworth Mary Ross, Reichman Marsha E., Unger Ellis F., Dabigatran and Postmarketing Reports of Bleeding, 10.1056/nejmp1302834
  14. Thrombosis and Haemostasis, 110, 1087 (2013)
  15. Journal of Thrombosis and Haemostasis, 11, 1203 (2013)
  16. Desai J., Kolb J. M., Weitz J. I., Aisenberg J., Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies : , 10.1160/th13-02-0150
  17. McConeghy Kevin W., Bress Adam, Qato Dima M., Wing Coady, Nutescu Edith A., Evaluation of Dabigatran Bleeding Adverse Reaction Reports in the FDA Adverse Event Reporting System during the First Year of Approval, 10.1002/phar.1415
  18. Eikelboom John W., Wallentin Lars, Connolly Stuart J., Ezekowitz Mike, Healey Jeff S., Oldgren Jonas, Yang Sean, Alings Marco, Kaatz Scott, Hohnloser Stefan H., Diener Hans-Christoph, Franzosi Maria Grazia, Huber Kurt, Reilly Paul, Varrone Jeanne, Yusuf Salim, Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationClinical Perspective : An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial, 10.1161/circulationaha.110.004747
  19. Frost Charles, Nepal Sunil, Wang Jessie, Schuster Alan, Byon Wonkyung, Boyd Rebecca A., Yu Zhigang, Shenker Andrew, Barrett Yu Chen, Mosqueda-Garcia Rogelio, LaCreta Frank, Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects : Apixaban multiple dose safety, PK and PD, 10.1111/bcp.12106
  20. Mueck Wolfgang, Stampfuss Jan, Kubitza Dagmar, Becka Michael, Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban, 10.1007/s40262-013-0100-7
  21. Clinical and Applied Thrombosis/Hemostasis, 15, 9S (2009)
  22. Revue Médicale Suisse, 10, 326 (2014)
  23. Circulation Cardiovascular Quality and Outcomes, 5, 615 (2012)
  24. Medical Journal of Australia, 198, 314 (2013)
  25. BMJ Open, 3, article e002758 (2013)
  26. The American Journal of Cardiology, 113, 650 (2014)
  27. Escobar Carlos, Barrios Vivencio, Dabigatran and Bleeding Risk: The Importance of a Correct Prescription, 10.1016/j.jemermed.2013.08.121
  28. European Journal of Clinical Pharmacology, 70, 249 (2014)
  29. Pfeilschifter Waltraud, Luger Sebastian, Brunkhorst Robert, Lindhoff-Last Edelgard, Foerch Christian, The Gap between Trial Data and Clinical Practice - An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation, 10.1159/000352062
  30. BMJ Open, 3, article e002686 (2013)
  31. BMJ Open, 3, article e003343 (2013)
  32. Pharmacotherapy, 32, article 2 (2012)
  33. Patel Jignesh P., Roberts Lara N., Arya Roopen, Anticoagulating obese patients in the modern era : Review, 10.1111/j.1365-2141.2011.08826.x
  34. Upreti Vijay V., Wang Jessie, Barrett Yu Chen, Byon Wonkyung, Boyd Rebecca A., Pursley Janice, LaCreta Frank P., Frost Charles E., Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects : Effect of extremes of body weight on the PK/PD of apixaban, 10.1111/bcp.12114
  35. Clinical Pharmacokinetics, 52, 243 (2013)
  36. British Journal of Clinical Pharmacology, 76, 89 (2013)
  37. Clinical Pharmacology & Therapeutics, 85, S34 (2009)
  38. Europace, 15, 625 (2013)
  39. Thrombosis and Haemostasis, 110, 1074 (2013)
  40. Journal of Thrombosis and Haemostasis, 11, 1647 (2013)
  41. Journal of the American College of Cardiology, 63, 321 (2014)
  42. ten Cate H., Monitoring new oral anticoagulants, managing thrombosis, or both? : , 10.1160/th12-03-0130
  43. Thrombosis Journal, 11, article 22 (2013)
  44. Drug Development Research, 74, article 7 (2013)
  45. Thrombosis Journal, 11, article 8 (2013)
  46. Baglin Trevor, Keeling David, Kitchen Steve, Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology, 10.1111/bjh.12052
  47. Thrombosis and Haemostasis, 108, 876 (2012)
  48. Baglin T., Hillarp A., Tripodi A., Elalamy I., Buller H., Ageno W., Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, 10.1111/jth.12149
  49. Pernod Gilles, Albaladejo Pierre, Godier Anne, Samama Charles M., Susen Sophie, Gruel Yves, Blais Normand, Fontana Pierre, Cohen Ariel, Llau Juan V., Rosencher Nadia, Schved Jean-François, de Maistre Emmanuel, Samama Meyer M., Mismetti Patrick, Sié Pierre, Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013, 10.1016/j.acvd.2013.04.009
  50. Thrombosis and Haemostasis, 110, 283 (2013)
  51. Douxfils J., Tamigniau A., Chatelain B., Chatelain C., Wallemacq P., Dogné J.-M., Mullier F., Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban : , 10.1160/th13-04-0274
  52. Huisman M. V., Lip G. Y. H., Diener H.-C., Brueckmann M., van Ryn J., Clemens A., Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice : , 10.1160/th11-10-0718
  53. Baron Todd H., Kamath Patrick S., McBane Robert D., Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures, 10.1056/nejmra1206531
  54. Kozek-Langenecker Sibylle A., Perioperative Management Issues of Direct Oral Anticoagulants, 10.1053/j.seminhematol.2014.02.001
  55. Internal and Emergency Medicine, 8, 477 (2013)
  56. Sié Pierre, Samama Charles M., Godier Anne, Rosencher Nadia, Steib Annick, Llau Juan V., Van der Linden Philippe, Pernod Gilles, Lecompte Thomas, Gouin-Thibault Isabelle, Albaladejo Pierre, Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis, 10.1016/j.acvd.2011.09.001
  57. Spyropoulos A. C., Douketis J. D., How I treat anticoagulated patients undergoing an elective procedure or surgery, 10.1182/blood-2012-06-415943
  58. Gogarten Wiebke, Vandermeulen Erik, Van Aken Hugo, Kozek Sibylle, Llau Juan V, Samama Charles M, Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology : , 10.1097/eja.0b013e32833f6f6f
  59. Anesthesiology, 118, 1466 (2013)
  60. Journal of Thrombosis and Thrombolysis, 36, 195 (2013)
  61. Blood, 123, 1152 (2014)
  62. Circulation, 128, 2325 (2013)
  63. Thrombosis and Haemostasis, 111, 189 (2014)
  64. Annals of Pharmacotherapy, 46, article e21 (2012)
  65. Critical Care, 18, article r27 (2014)
  66. Lu Genmin, DeGuzman Francis R, Hollenbach Stanley J, Karbarz Mark J, Abe Keith, Lee Gail, Luan Peng, Hutchaleelaha Athiwat, Inagaki Mayuko, Conley Pamela B, Phillips David R, Sinha Uma, A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, 10.1038/nm.3102
  67. Thrombosis Journal, 11, article 27 (2013)
  68. Majeed Ammar, Schulman Sam, Bleeding and antidotes in new oral anticoagulants, 10.1016/j.beha.2013.07.001